BioSight Success in Leukemia Trial

Cancer treatment company BioSight, which recently received a $13 million investment from Mori Arkin and US investment fund Primera Capital, reports positive interim results of an initial efficacy trial for its Leukemia treatment product. The company’s product, Astarabine, had been tested on 15 Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) patients unfit for chemotherapy, due to its toxicity. While it is impossible to discuss the significance of the results, since the trial was conducted with no control group (as customary with trials on cancer at this stage), results indicate a good response to treatment in the examined group, with minimum side effects. In three out of 15 patients, for whom no treatment could earlier be provided, a full remission was noted for 4-10 months, to date; in two further patients a partial remission was reported for 3-7 months.

Written by

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Etiam libero diam, elementum eget porttitor at, tincidunt at nulla.